BR9408323A - Derivados de rapamicina - Google Patents

Derivados de rapamicina

Info

Publication number
BR9408323A
BR9408323A BR9408323A BR9408323A BR9408323A BR 9408323 A BR9408323 A BR 9408323A BR 9408323 A BR9408323 A BR 9408323A BR 9408323 A BR9408323 A BR 9408323A BR 9408323 A BR9408323 A BR 9408323A
Authority
BR
Brazil
Prior art keywords
pct
rapamycin derivatives
date jun
sec
rapamycin
Prior art date
Application number
BR9408323A
Other languages
English (en)
Inventor
Sylvain Dr Cottens
Richard Dr Sedrani
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939325802A external-priority patent/GB9325802D0/en
Priority claimed from GB939325800A external-priority patent/GB9325800D0/en
Priority claimed from GB9407138A external-priority patent/GB9407138D0/en
Priority claimed from GB9421982A external-priority patent/GB9421982D0/en
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of BR9408323A publication Critical patent/BR9408323A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BR9408323A 1993-12-17 1994-12-16 Derivados de rapamicina BR9408323A (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB939325802A GB9325802D0 (en) 1993-12-17 1993-12-17 Organic compounds
GB939325800A GB9325800D0 (en) 1993-12-17 1993-12-17 Organic compounds
GB9407138A GB9407138D0 (en) 1994-04-11 1994-04-11 Organic compounds
GB9421982A GB9421982D0 (en) 1994-11-01 1994-11-01 Organic compounds
PCT/EP1994/004191 WO1995016691A1 (en) 1993-12-17 1994-12-16 Rapamycin derivatives useful as immunosuppressants

Publications (1)

Publication Number Publication Date
BR9408323A true BR9408323A (pt) 1997-08-19

Family

ID=27451097

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9408323A BR9408323A (pt) 1993-12-17 1994-12-16 Derivados de rapamicina

Country Status (21)

Country Link
US (1) US5912253A (pt)
EP (1) EP0734389B1 (pt)
JP (1) JP3745772B2 (pt)
CN (1) CN1046944C (pt)
AT (1) ATE191218T1 (pt)
AU (1) AU687491B2 (pt)
BR (1) BR9408323A (pt)
CZ (1) CZ284650B6 (pt)
DE (1) DE69423781T2 (pt)
DK (1) DK0734389T3 (pt)
ES (1) ES2146741T3 (pt)
FI (1) FI962487A (pt)
GR (1) GR3033545T3 (pt)
HU (1) HUT74686A (pt)
NO (1) NO962540L (pt)
NZ (1) NZ277498A (pt)
PL (1) PL314238A1 (pt)
PT (1) PT734389E (pt)
SG (1) SG64372A1 (pt)
SK (1) SK78196A3 (pt)
WO (1) WO1995016691A1 (pt)

Families Citing this family (226)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
WO1994025022A1 (en) 1993-04-23 1994-11-10 Abbott Laboratories Rapamycin conjugates and antibodies
US7279561B1 (en) * 1993-04-23 2007-10-09 Wyeth Anti-rapamycin monoclonal antibodies
US6187757B1 (en) 1995-06-07 2001-02-13 Ariad Pharmaceuticals, Inc. Regulation of biological events using novel compounds
KR100400620B1 (ko) 1995-06-09 2004-02-18 노파르티스 아게 라파마이신유도체
GB9606452D0 (en) * 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds
US6984635B1 (en) 1998-02-13 2006-01-10 Board Of Trustees Of The Leland Stanford Jr. University Dimerizing agents, their production and use
ATE556713T1 (de) 1999-01-13 2012-05-15 Bayer Healthcare Llc Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7063857B1 (en) 1999-04-30 2006-06-20 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
US7067526B1 (en) 1999-08-24 2006-06-27 Ariad Gene Therapeutics, Inc. 28-epirapalogs
EP1212331B1 (en) 1999-08-24 2004-04-21 Ariad Gene Therapeutics, Inc. 28-epirapalogs
EP1210121A2 (en) 1999-08-24 2002-06-05 Cellgate Inc. Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
US6790228B2 (en) 1999-12-23 2004-09-14 Advanced Cardiovascular Systems, Inc. Coating for implantable devices and a method of forming the same
US7807211B2 (en) 1999-09-03 2010-10-05 Advanced Cardiovascular Systems, Inc. Thermal treatment of an implantable medical device
US8236048B2 (en) 2000-05-12 2012-08-07 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
US6776796B2 (en) * 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device
US7300662B2 (en) * 2000-05-12 2007-11-27 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
US20050002986A1 (en) * 2000-05-12 2005-01-06 Robert Falotico Drug/drug delivery systems for the prevention and treatment of vascular disease
EP1322235B2 (en) 2000-09-29 2010-08-11 Cordis Corporation Coated medical devices
US20040018228A1 (en) * 2000-11-06 2004-01-29 Afmedica, Inc. Compositions and methods for reducing scar tissue formation
US6534693B2 (en) * 2000-11-06 2003-03-18 Afmedica, Inc. Surgically implanted devices having reduced scar tissue formation
US20040241211A9 (en) * 2000-11-06 2004-12-02 Fischell Robert E. Devices and methods for reducing scar tissue formation
JP2004526425A (ja) * 2000-11-28 2004-09-02 ワイス 前立腺癌の診断および治療に有用なｆｋｂｐ核酸およびポリペプチドの発現分析
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
AU2005201004A1 (en) * 2001-02-19 2005-03-24 Novartis Ag Cancer treatment
AU2011226833B9 (en) * 2001-02-19 2014-07-03 Novartis Ag Cancer treatment
AU2016206379B2 (en) * 2001-02-19 2017-09-14 Novartis Ag Cancer Treatment
ES2705016T3 (es) 2001-02-19 2019-03-21 Novartis Int Pharmaceutical Ag Derivado de rapamicina para el tratamiento de cáncer de pulmón
US7682387B2 (en) 2002-04-24 2010-03-23 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US6939376B2 (en) * 2001-11-05 2005-09-06 Sun Biomedical, Ltd. Drug-delivery endovascular stent and method for treating restenosis
EP1458405A1 (en) * 2001-11-21 2004-09-22 Sucampo AG Use of fk506 and analogues for treating allergic diseases
AU2003209116A1 (en) 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
US20040072796A1 (en) * 2002-04-18 2004-04-15 Embury Stephen H. Method and composition for preventing pain in sickle cell patients
US20040024450A1 (en) * 2002-04-24 2004-02-05 Sun Biomedical, Ltd. Drug-delivery endovascular stent and method for treating restenosis
NZ560662A (en) 2002-05-16 2009-09-25 Novartis Ag Use of EDG receptor binding agents in cancer
JP4265888B2 (ja) * 2002-06-12 2009-05-20 株式会社リコー 画像形成装置
US7300942B2 (en) 2002-07-16 2007-11-27 Biotica Technology Limited Production of polyketides and other natural products
CN1708293A (zh) 2002-09-24 2005-12-14 诺瓦提斯公司 治疗脱髓鞘疾病的鞘氨醇－1－磷酸受体激动剂
WO2004060283A2 (en) 2002-12-16 2004-07-22 Nitromed, Inc. Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use
JP2006516548A (ja) 2002-12-30 2006-07-06 アンジオテック インターナショナル アクツィエン ゲゼルシャフト 迅速ゲル化ポリマー組成物からの薬物送達法
JP4860474B2 (ja) 2003-05-20 2012-01-25 バイエル、ファーマシューテイカルズ、コーポレイション Ｐｄｇｆｒによって仲介される病気のためのジアリール尿素
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
CN102144961A (zh) * 2003-09-18 2011-08-10 参天制药株式会社 经巩膜递送
US7220755B2 (en) * 2003-11-12 2007-05-22 Biosensors International Group, Ltd. 42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same
US7780973B2 (en) * 2003-12-15 2010-08-24 Ethicon Endo-Surgery, Inc. Method and device for minimally invasive implantation of biomaterial
US20050142161A1 (en) * 2003-12-30 2005-06-30 Freeman Lynetta J. Collagen matrix for soft tissue augmentation
EP1768662A2 (en) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
GB0417852D0 (en) 2004-08-11 2004-09-15 Biotica Tech Ltd Production of polyketides and other natural products
US7901451B2 (en) * 2004-09-24 2011-03-08 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US8021849B2 (en) * 2004-11-05 2011-09-20 Siemens Healthcare Diagnostics Inc. Methods and kits for the determination of sirolimus in a sample
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
BRPI0608152A2 (pt) * 2005-02-09 2009-11-10 Macusight Inc formulações para tratamento ocular
GB0504544D0 (en) 2005-03-04 2005-04-13 Novartis Ag Organic compounds
GB0504994D0 (en) * 2005-03-11 2005-04-20 Biotica Tech Ltd Novel compounds
WO2006095173A2 (en) 2005-03-11 2006-09-14 Biotica Technology Limited Medical uses of 39-desmethoxyrapamycin and analogues thereof
US20100061994A1 (en) * 2005-03-11 2010-03-11 Rose Mary Sheridan Medical uses of 39-desmethoxyrapamycin and analogues thereof
US7189582B2 (en) * 2005-04-27 2007-03-13 Dade Behring Inc. Compositions and methods for detection of sirolimus
BRPI0613692A2 (pt) 2005-07-20 2011-01-25 Novartis Ag combinação farmacêutica e uso da mesma
PT2298815E (pt) 2005-07-25 2015-07-16 Emergent Product Dev Seattle Moléculas de ligaçao especificas para cd37 e especificas para cd20
WO2007027751A2 (en) 2005-08-30 2007-03-08 University Of Miami Immunomodulating tumor necrosis factor receptor 25 (tnfr25) agonists, antagonists and immunotoxins
KR20140093764A (ko) 2006-02-09 2014-07-28 산텐 세이야꾸 가부시키가이샤 안정한 제제와 그 제조 및 사용 방법
CN103127100A (zh) * 2006-03-23 2013-06-05 参天制药株式会社 用于与血管通透性有关的疾病或病症的制剂和方法
GB0609962D0 (en) * 2006-05-19 2006-06-28 Biotica Tech Ltd Novel compounds
GB0609963D0 (en) * 2006-05-19 2006-06-28 Biotica Tech Ltd Novel compounds
US7883855B2 (en) 2006-07-21 2011-02-08 Abbott Laboratories Immunosuppressant drug extraction reagent for immunoassays
US20080097591A1 (en) 2006-10-20 2008-04-24 Biosensors International Group Drug-delivery endovascular stent and method of use
US8067055B2 (en) * 2006-10-20 2011-11-29 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method of use
US20080103584A1 (en) * 2006-10-25 2008-05-01 Biosensors International Group Temporal Intraluminal Stent, Methods of Making and Using
WO2008083169A2 (en) 2006-12-26 2008-07-10 The Johns Hopkins University Compositions and methods for the treatment of immunologic disorders
EP2586458B1 (en) 2006-12-27 2016-08-24 The Johns Hopkins University Compositions and methods for treating inflammation and auto-immune diseases
US7989173B2 (en) 2006-12-27 2011-08-02 The Johns Hopkins University Detection and diagnosis of inflammatory disorders
US7914999B2 (en) 2006-12-29 2011-03-29 Abbott Laboratories Non-denaturing lysis reagent
ES2393135T3 (es) 2006-12-29 2012-12-18 Abbott Laboratories Ensayo mejorado para fármacos inmunosupresores
EP2118654B1 (en) 2006-12-29 2013-03-27 Abbott Laboratories Diagnostic test for the detection of a molecule or drug in whole blood
EP2118657B1 (en) 2006-12-29 2014-05-21 Abbott Laboratories Non-denaturing lysis reagent for use with capture-in-solution immunoassay
US20080265343A1 (en) * 2007-04-26 2008-10-30 International Business Machines Corporation Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
KR100930167B1 (ko) * 2007-09-19 2009-12-07 삼성전기주식회사 초광각 광학계
WO2009089549A1 (en) 2008-01-11 2009-07-16 Massachusetts Eye & Ear Infirmary Conditional-stop dimerizable caspase transgenic animals
US20100048913A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
WO2009126944A1 (en) 2008-04-11 2009-10-15 Trubion Pharmaceuticals, Inc. Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
CA2728514C (en) 2008-06-20 2020-08-11 Novartis Ag Paediatric compositions for treating multiple sclerosis
US20120064143A1 (en) 2008-11-11 2012-03-15 The Board Of Regents Of The University Of Texas System Inhibition of mammalian target of rapamycin
EP2393827B1 (en) 2009-02-05 2015-10-07 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
CN101924315B (zh) * 2009-06-16 2014-09-03 德昌电机(深圳)有限公司 换向器及其制造方法
AU2010279637B2 (en) 2009-08-03 2012-08-23 University Of Miami Method for in vivo expansion of T regulatory cells
US9005616B2 (en) 2009-08-31 2015-04-14 Amplimmune, Inc. Methods and compositions for the inhibition of transplant rejection
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
ES2689177T3 (es) 2010-04-13 2018-11-08 Novartis Ag Combinación que comprende un inhibidor de cinasa 4 dependiente de ciclina o cinasa dependiente de ciclina (CDK4/6) y un inhibidor de mTOR para tratar cáncer
EP2558082A1 (en) 2010-04-16 2013-02-20 Novartis AG Combination of organic compounds
CA2795544A1 (en) 2010-04-27 2011-11-03 Roche Glycart Ag Combination therapy of an afucosylated cd20 antibody with a mtor inhibitor
PT2675451E (pt) 2011-02-18 2015-10-16 Incyte Corp Terapia de combinação com inibidores mtor/jak
UA110961C2 (uk) 2011-04-25 2016-03-10 Новартіс Аг КОМБІНАЦІЯ ІНГІБІТОРУ ФОСФАТИДИЛІНОЗИТ-3-КІНАЗИ (PI3K) І ІНГІБІТОРУ mTOR
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
EP2589383A1 (en) 2011-11-06 2013-05-08 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin FKBP subtype-specific rapamycin analogue for use in treatment of diseases
JP2014533294A (ja) 2011-11-15 2014-12-11 ノバルティス アーゲー ホスホイノシチド３−キナーゼ阻害剤およびヤヌスキナーゼ２−シグナル伝達兼転写活性化因子５経路の調節剤の組合せ
GB201122305D0 (en) 2011-12-23 2012-02-01 Biotica Tech Ltd Novel compound
WO2013155493A1 (en) 2012-04-12 2013-10-17 Yale University Methods of treating inflammatory and autoimmune diseases and disorders
WO2013192367A1 (en) 2012-06-22 2013-12-27 Novartis Ag Neuroendocrine tumor treatment
WO2014006115A1 (en) 2012-07-06 2014-01-09 Novartis Ag Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the il-8/cxcr interaction
EP2906214A1 (en) 2012-10-12 2015-08-19 The Board of Regents of The University of Texas System Use of mtor inhibitors to treat vascular cognitive impairment
EP2919759A4 (en) 2012-11-14 2016-07-20 Ohio State Innovation Foundation MATERIALS AND METHODS FOR THE TREATMENT OF GLIOBLASTOMES
CA2894689A1 (en) 2012-12-19 2014-06-26 Amplimmune, Inc. Anti-human b7-h4 antibodies and their uses
KR20210041631A (ko) 2013-01-09 2021-04-15 유니버시티 오브 마이애미 TL1A-Ig 융합 단백질을 사용한 T 조절 세포의 조절을 위한 조성물 및 방법
WO2014160328A1 (en) 2013-03-13 2014-10-02 The Board Of Regents Of The University Of Texas System Mtor inhibitors for prevention of intestinal polyp growth
US9884067B2 (en) 2013-03-14 2018-02-06 University Of Maryland, Baltimore Androgen receptor down-regulating agents and uses thereof
US20160146806A1 (en) 2013-05-17 2016-05-26 Amplimmune, Inc. Receptors for b7-h4
CA2905229C (en) 2013-06-11 2023-10-10 Clontech Laboratories, Inc. Protein enriched microvesicles and methods of making and using the same
US9808472B2 (en) 2013-08-12 2017-11-07 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
US9580758B2 (en) 2013-11-12 2017-02-28 Luc Montagnier System and method for the detection and treatment of infection by a microbial agent associated with HIV infection
KR20160084438A (ko) 2013-11-13 2016-07-13 노파르티스 아게 면역 반응을 강화하기 위한 mTOR 억제제
CA3225453A1 (en) 2013-12-19 2015-06-25 Novartis Ag Human mesothelin chimeric antigen receptors and uses thereof
EP3087101B1 (en) 2013-12-20 2024-06-05 Novartis AG Regulatable chimeric antigen receptor
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
AU2014373683B2 (en) 2013-12-31 2020-05-07 Rapamycin Holdings, Llc Oral rapamycin nanoparticle preparations and use
KR20160110963A (ko) 2014-02-11 2016-09-23 노파르티스 아게 암 치료를 위한 pi3k 억제제를 포함하는 제약 조합물
JP2017513818A (ja) 2014-03-15 2017-06-01 ノバルティス アーゲー キメラ抗原受容体を使用する癌の処置
EP3811970A1 (en) 2014-03-15 2021-04-28 Novartis AG Regulatable chimeric antigen receptor
EP3122376A4 (en) 2014-03-27 2017-12-20 The Brigham and Women's Hospital, Inc. Metabolically-activated drug conjugates to overcome resistance in cancer therapy
HUE054588T2 (hu) 2014-04-07 2021-09-28 Novartis Ag Rák kezelése CD19 elleni, kiméra antigénreceptor alkalmazásával
CA2968049A1 (en) 2014-04-16 2015-10-22 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
WO2015171723A1 (en) 2014-05-06 2015-11-12 Research Development Foundation Methods for treating insulin resistance and for sensitizing patients to glp1 agonist therapy
WO2015187541A1 (en) 2014-06-02 2015-12-10 Children's Medical Center Corporation Methods and compositions for immunomodulation
CA2955154C (en) 2014-07-21 2023-10-31 Novartis Ag Treatment of cancer using a cd33 chimeric antigen receptor
EP3193915A1 (en) 2014-07-21 2017-07-26 Novartis AG Combinations of low, immune enhancing. doses of mtor inhibitors and cars
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
EP4205749A1 (en) 2014-07-31 2023-07-05 Novartis AG Subset-optimized chimeric antigen receptor-containing cells
CA2958200A1 (en) 2014-08-14 2016-02-18 Novartis Ag Treatment of cancer using a gfr alpha-4 chimeric antigen receptor
PL3183268T3 (pl) 2014-08-19 2020-09-07 Novartis Ag Chimeryczny receptor antygenowy (CAR) anty-CD123 do zastosowania w leczeniu nowotworu złośliwego
CN113620978A (zh) 2014-09-11 2021-11-09 加利福尼亚大学董事会 mTORC1抑制剂
WO2016044605A1 (en) 2014-09-17 2016-03-24 Beatty, Gregory Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
KR20170068504A (ko) 2014-10-08 2017-06-19 노파르티스 아게 키메라 항원 수용체 요법에 대한 치료 반응성을 예측하는 바이오마커 및 그의 용도
EP3977995A1 (en) 2014-10-28 2022-04-06 Koushi Yamaguchi Tacrolimus for ameliorating pregnancy conditions
WO2016066608A1 (en) 2014-10-28 2016-05-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of pulmonary cell senescence and peripheral aging
FR3033499A1 (fr) 2015-03-11 2016-09-16 Centre Leon-Berard Composition pour le traitement des tumeurs neuroendocrines pancreatiques
ES2876974T3 (es) 2015-04-07 2021-11-15 Novartis Ag Combinación de terapia con receptor de antígeno quimérico y derivados de amino pirimidina
CA2982996A1 (en) 2015-04-17 2016-10-20 David Maxwell Barrett Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
EP3286211A1 (en) 2015-04-23 2018-02-28 Novartis AG Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
CN106188093B (zh) * 2015-05-08 2018-06-12 上海医药工业研究院 一种雷帕霉素结构类似物及其制备方法
JP6857141B2 (ja) 2015-05-20 2021-04-14 ノバルティス アーゲー エベロリムスとダクトリシブとの薬学的組合せ
CA2997442C (en) 2015-09-04 2021-01-26 Yale University Polymeric bile acid nanocompositions targeting the pancreas and colon
WO2017081624A1 (en) 2015-11-11 2017-05-18 Novartis Ag Uses of myostatin antagonists, combinations containing them and uses thereof
US20190117799A1 (en) 2016-04-01 2019-04-25 The Brigham And Women's Hospital, Inc. Stimuli-responsive nanoparticles for biomedical applications
WO2017190145A1 (en) 2016-04-29 2017-11-02 Icahn School Of Medicine At Mount Sinai Targeting the innate immune system to induce long-term tolerance and to resolve macrophage accumulation in atherosclerosis
US11365252B2 (en) 2016-07-20 2022-06-21 University Of Utah Research Foundation CD229 CAR T cells and methods of use thereof
KR102644544B1 (ko) 2016-09-21 2024-03-11 넥스트큐어 인코포레이티드 Siglec-15를 위한 항체 및 이의 사용 방법
CN117866991A (zh) 2016-10-07 2024-04-12 诺华股份有限公司 用于治疗癌症的嵌合抗原受体
CA3044355A1 (en) 2016-11-23 2018-05-31 Novartis Ag Methods of enhancing immune response with everolimus, dactolisib or both
WO2018100190A1 (en) 2016-12-02 2018-06-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for diagnosing renal cell carcinoma
JOP20190154B1 (ar) 2016-12-22 2022-09-15 Amgen Inc بنز أيزو ثيازول، أيزو ثيازولو [3، 4-b] بيريدين، كينازولين، فثالازين، بيريدو [2، 3-d] بيريدازين ومشتقات بيريدو [2، 3-d] بيريميدين على هيئة مثبطات kras g12c لمعالجة سرطان الرئة، أو سرطان البنكرياس أو سرطان القولون والمستقيم
AU2018219317A1 (en) 2017-02-10 2019-09-26 Mount Tam Therapeutics, Inc. Rapamycin analog
US20200055948A1 (en) 2017-04-28 2020-02-20 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
ES2871499T3 (es) 2017-05-15 2021-10-29 Bard Inc C R Dispositivo médico con recubrimiento de elución de fármaco y capa intermedia
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
EP4141005B1 (en) 2017-09-08 2024-04-03 Amgen Inc. Inhibitors of kras g12c and methods of using the same
WO2019157516A1 (en) 2018-02-12 2019-08-15 resTORbio, Inc. Combination therapies
US20210047405A1 (en) 2018-04-27 2021-02-18 Novartis Ag Car t cell therapies with enhanced efficacy
FI3788049T3 (fi) 2018-05-01 2023-05-30 Revolution Medicines Inc C40-, c28- ja c-32-liittyneitä rapamysiinianalogeja mtor-estäjinä
EP3788369A1 (en) 2018-05-01 2021-03-10 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
IL312291A (en) 2018-05-01 2024-06-01 Revolution Medicines Inc C-26-linked rapamycin analogs as MTOR inhibitors
MX2020010836A (es) 2018-05-04 2021-01-08 Amgen Inc Inhibidores de kras g12c y métodos para su uso.
WO2019213526A1 (en) 2018-05-04 2019-11-07 Amgen Inc. Kras g12c inhibitors and methods of using the same
WO2019217661A1 (en) 2018-05-09 2019-11-14 Yale University Compositions and systems for ex vivo cell modulation and methods of use thereof
WO2019217552A1 (en) 2018-05-09 2019-11-14 Yale University Particles for spatiotemporal release of agents
MA52564A (fr) 2018-05-10 2021-03-17 Amgen Inc Inhibiteurs de kras g12c pour le traitement du cancer
MA52765A (fr) 2018-06-01 2021-04-14 Amgen Inc Inhibiteurs de kras g12c et leurs procédés d'utilisation
MA52780A (fr) 2018-06-11 2021-04-14 Amgen Inc Inhibiteurs de kras g12c pour le traitement du cancer
MA51848A (fr) 2018-06-12 2021-04-21 Amgen Inc Inhibiteurs de kras g12c et leurs procédés d'utilisation
JP7382353B2 (ja) * 2018-06-15 2023-11-16 ヤンセン ファーマシューティカ エヌ．ベー． ラパマイシン類似体およびその使用
EP3834826A4 (en) 2018-08-10 2022-07-27 Koushi Yamaguchi THERAPEUTIC AGENT FOR HUMORAL IMMUNITY-RELATED DISEASES IN THE MATERNO-FETAL RELATIONSHIP
EP3880266A1 (en) 2018-11-14 2021-09-22 Lutonix, Inc. Medical device with drug-eluting coating on modified device surface
CA3117221A1 (en) 2018-11-16 2020-05-22 Amgen Inc. Improved synthesis of key intermediate of kras g12c inhibitor compound
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
AU2019384118A1 (en) 2018-11-19 2021-05-27 Amgen Inc. KRAS G12C inhibitors and methods of using the same
US20220062245A1 (en) 2018-12-18 2022-03-03 Koushi Yamaguchi Agent for improving infertility, recurrent miscarriage, and state of pregnancy
WO2020132651A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Kif18a inhibitors
MA54546A (fr) 2018-12-20 2022-03-30 Amgen Inc Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a
CA3123044A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Heteroaryl amides useful as kif18a inhibitors
CN113226473A (zh) 2018-12-20 2021-08-06 美国安进公司 Kif18a抑制剂
KR102643707B1 (ko) * 2019-01-22 2024-03-04 에오비안 파마슈티컬스, 인크. Mtorc 조절제 및 이의 용도
KR20210146287A (ko) 2019-03-01 2021-12-03 레볼루션 메디슨즈, 인크. 이환식 헤테로아릴 화합물 및 이의 용도
CN113727758A (zh) 2019-03-01 2021-11-30 锐新医药公司 双环杂环基化合物及其用途
US20220176084A1 (en) 2019-04-08 2022-06-09 Bard Peripheral Vascular, Inc. Medical device with drug-eluting coating on modified device surface
EP3738593A1 (en) 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
CN114144414A (zh) 2019-05-21 2022-03-04 美国安进公司 固态形式
TW202114681A (zh) 2019-07-02 2021-04-16 美商ｅＦＦＥＣＴＯＲ醫療公司 轉譯抑制劑及其用途
CN114401953A (zh) 2019-08-02 2022-04-26 美国安进公司 Kif18a抑制剂
JP2022542392A (ja) 2019-08-02 2022-10-03 アムジエン・インコーポレーテツド Ｋｉｆ１８ａ阻害剤としてのピリジン誘導体
AU2020326627A1 (en) 2019-08-02 2022-03-17 Amgen Inc. KIF18A inhibitors
AU2020324963A1 (en) 2019-08-02 2022-02-24 Amgen Inc. KIF18A inhibitors
WO2021055728A1 (en) 2019-09-18 2021-03-25 Merck Sharp & Dohme Corp. Small molecule inhibitors of kras g12c mutant
WO2021081212A1 (en) 2019-10-24 2021-04-29 Amgen Inc. Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer
MX2022005053A (es) 2019-10-28 2022-05-18 Merck Sharp & Dohme Llc Inhibidores de peque?as moleculas de mutante g12c de kras.
WO2021085653A1 (en) 2019-10-31 2021-05-06 Taiho Pharmaceutical Co., Ltd. 4-aminobut-2-enamide derivatives and salts thereof
TW202132314A (zh) 2019-11-04 2021-09-01 美商銳新醫藥公司 Ｒａｓ抑制劑
CN115873020A (zh) 2019-11-04 2023-03-31 锐新医药公司 Ras抑制剂
BR112022008565A2 (pt) 2019-11-04 2022-08-09 Revolution Medicines Inc Composto, composição farmacêutica, conjugado, métodos para tratar câncer e um distúrbio relativo à proteína ras
KR20220100903A (ko) 2019-11-08 2022-07-18 레볼루션 메디슨즈, 인크. 이환식 헤테로아릴 화합물 및 이의 용도
MX2022005708A (es) 2019-11-14 2022-06-08 Amgen Inc Sintesis mejorada del compuesto inhibidor de g12c de kras.
AR120456A1 (es) 2019-11-14 2022-02-16 Amgen Inc Síntesis mejorada del compuesto inhibidor de g12c de kras
CN114980976A (zh) 2019-11-27 2022-08-30 锐新医药公司 共价ras抑制剂及其用途
WO2021106231A1 (en) 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
EP4069223A4 (en) * 2019-12-05 2023-12-20 Janssen Pharmaceutica NV RAPAMYCIN ANALOGS AND THEIR USES
AU2021206217A1 (en) 2020-01-07 2022-09-01 Revolution Medicines, Inc. SHP2 inhibitor dosing and methods of treating cancer
JP2023530778A (ja) 2020-03-27 2023-07-19 エオビアン ファーマシューティカルズ， インコーポレイテッド Ｍｔｏｒｃ１モジュレーターおよびその使用
US20230181536A1 (en) 2020-04-24 2023-06-15 Taiho Pharmaceutical Co., Ltd. Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c
EP4139299A1 (en) 2020-04-24 2023-03-01 Taiho Pharmaceutical Co., Ltd. Kras g12d protein inhibitors
CN116600789A (zh) 2020-06-19 2023-08-15 耶鲁大学 用于诱导耐受性的聚合胆汁酸酯纳米颗粒
WO2022014640A1 (ja) 2020-07-15 2022-01-20 大鵬薬品工業株式会社 腫瘍の治療に使用されるピリミジン化合物を含む組み合わせ
EP4185590A2 (en) * 2020-07-21 2023-05-31 Aeovian Pharmaceuticals, Inc. Mtorc1 modulators and uses thereof
IL301062A (en) 2020-09-03 2023-05-01 Revolution Medicines Inc Use of SOS1 inhibitors to treat malignancies with SHP2 mutations
AU2021345111A1 (en) 2020-09-15 2023-04-06 Revolution Medicines, Inc. Indole derivatives as Ras inhibitors in the treatment of cancer
CN117396472A (zh) 2020-12-22 2024-01-12 上海齐鲁锐格医药研发有限公司 Sos1抑制剂及其用途
EP4308105A1 (en) 2021-03-19 2024-01-24 Trained Therapeutix Discovery, Inc. Compounds for regulating trained immunity, and their methods of use
MX2023013084A (es) 2021-05-05 2023-11-17 Revolution Medicines Inc Inhibidores de ras para el tratamiento del cancer.
CA3217393A1 (en) 2021-05-05 2022-11-10 Elena S. Koltun Ras inhibitors
JP2024516450A (ja) 2021-05-05 2024-04-15 レボリューション メディシンズ インコーポレイテッド 共有結合性ｒａｓ阻害剤及びその使用
JP2024521979A (ja) 2021-05-28 2024-06-04 大鵬薬品工業株式会社 Ｋｒａｓ変異タンパク質の小分子阻害剤関連出願の相互参照
CA3223081A1 (en) 2021-07-15 2023-01-19 Samir Mitragotri Compositions and methods relating to cells with adhered particles
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
WO2023114954A1 (en) 2021-12-17 2023-06-22 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2024081916A1 (en) 2022-10-14 2024-04-18 Black Diamond Therapeutics, Inc. Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2881886B2 (ja) * 1989-12-30 1999-04-12 ソニー株式会社 映像信号符号化方法及びその装置
US5221670A (en) * 1990-09-19 1993-06-22 American Home Products Corporation Rapamycin esters
PT98990A (pt) * 1990-09-19 1992-08-31 American Home Prod Processo para a preparacao de esteres de acidos carboxilicos de rapamicina
US5120842A (en) * 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5100883A (en) * 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
US5118678A (en) * 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
US5118677A (en) * 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
US5151413A (en) * 1991-11-06 1992-09-29 American Home Products Corporation Rapamycin acetals as immunosuppressant and antifungal agents
ZA935112B (en) * 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
US5256790A (en) * 1992-08-13 1993-10-26 American Home Products Corporation 27-hydroxyrapamycin and derivatives thereof
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5262423A (en) * 1992-10-29 1993-11-16 American Home Products Corporation Rapamycin arylcarbonyl and alkoxycarbonyl carbamates as immunosuppressive and antifungal agents
US5258389A (en) * 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
US5310903A (en) * 1993-03-05 1994-05-10 Merck & Co., Inc. Imidazolidyl rapamycin derivatives
US5310901A (en) * 1993-03-05 1994-05-10 Merck & Co., Inc. O-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynlheteroarylrapamycin derivatives
US5527907A (en) * 1993-11-19 1996-06-18 Abbott Laboratories Macrolide immunomodulators
CA2175215C (en) * 1993-11-19 2008-06-03 Yat Sun Or Semisynthetic analogs of rapamycin (macrolides) being immunomodulators

Also Published As

Publication number Publication date
WO1995016691A1 (en) 1995-06-22
FI962487A0 (fi) 1996-06-14
DK0734389T3 (da) 2000-08-21
FI962487A (fi) 1996-06-14
HU9601643D0 (en) 1996-08-28
CZ175796A3 (en) 1996-09-11
DE69423781D1 (de) 2000-05-04
NO962540D0 (no) 1996-06-14
PL314238A1 (en) 1996-09-02
CN1046944C (zh) 1999-12-01
AU687491B2 (en) 1998-02-26
JP3745772B2 (ja) 2006-02-15
DE69423781T2 (de) 2000-08-10
ES2146741T3 (es) 2000-08-16
CN1137797A (zh) 1996-12-11
NO962540L (no) 1996-06-14
CZ284650B6 (cs) 1999-01-13
HUT74686A (en) 1997-01-28
NZ277498A (en) 1998-03-25
PT734389E (pt) 2000-09-29
JPH09506604A (ja) 1997-06-30
ATE191218T1 (de) 2000-04-15
US5912253A (en) 1999-06-15
AU1273995A (en) 1995-07-03
EP0734389A1 (en) 1996-10-02
SK78196A3 (en) 1997-02-05
SG64372A1 (en) 1999-04-27
GR3033545T3 (en) 2000-09-29
EP0734389B1 (en) 2000-03-29

Similar Documents

Publication Publication Date Title
BR9408323A (pt) Derivados de rapamicina
DK1140993T3 (da) Glycopeptidderivater og farmaceutiske præparater indeholdende dem
NO962286L (no) N-substituerte azabicykloalkanderivater som neuroleptika etc.
PL314188A1 (en) Novel derivatives of benzoguanidine, method of obtaining them and their application in pharmaceutical compositions
AU7495096A (en) New compounds and their compositions having anti-inflammatory and anti-thrombotic activities
MX9700885A (es) Nuevas heteroariloxazolidinonas.
AU5485698A (en) Oxyiminopregnancarbolactone
DK0695171T3 (da) Lyosfærer indeholdende gonadotropin
BR9811099A (pt) Inibidores de urocinase
ES2166823T3 (es) Nuevos derivados pirrolicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ES2192832T3 (es) Uso de compuestos macrolidos para tratar glaucoma.
BG102250A (en) The use of marigold-extracted glycosides for the treatment of psoriasis
CA2266759A1 (en) 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase
MY120683A (en) New phenylamidine derivatives, processes for their preparation and their use as pharmaceuticals.
CA2218663A1 (en) Benzisoxazole and indazole derivatives as antipsychotic agents
NO962285L (no) N-substituerte azabicykloheptan-derivater anvendt for eksempel som neuroleptika
DK0842185T3 (da) Ara-C-derivater
AU6087194A (en) Hiv protease inhibitors
AU6415994A (en) Substituted caprolactams and derivatives thereof useful for treatment of hiv disease
IL134930A0 (en) Benzoxazine and benzothiazine derivatives and pharmaceutical compositions containing the same
ES2163001T3 (es) Nuevos derivados de borneol, procedimiento para su preparacion y su utilizacion farmaceutica.
NO960812L (no) Alkoksysubstituerte ptoren
AU6722498A (en) Disubstituted biphenyloxazolines
MXPA03003466A (es) Derivados de piranosido.
SE9803277D0 (sv) Novel compounds

Legal Events

Date Code Title Description
EG Technical examination (opinion): publication of technical examination (opinion)
PC Transfer

Free format text: NOVARTIS AG (CH)

FC Decision: refusal